万邦德：关于子公司阿尔茨海默病项目入选创新药物研发国家科技重大专项的公告

Group 1 - The core point of the article is that Wanbangde's subsidiary has been selected for a national major science and technology project focused on innovative drug development for Alzheimer's disease [2] - The project is led by the Shanghai Institute of Materia Medica, which is part of the Chinese Academy of Sciences [2] - The company has received official approval from the National Health Commission's China Biotechnology Development Center for the project [2]